Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ri Liesner

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
British Journal of Haematology|March 24, 2020
Product type and the risk of inhibitor development in nonsevere haemophilia A patients: a case-control studyAlice S van Velzen, Corien L Eckhardt, Marjolein Peters, et al.
Haematologica|January 11, 2020
Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet studyChristoph Male, Nadine G Andersson, Anne Rafowicz, et al.
Blood|November 8, 2019
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitorsGuy Young, Ri Liesner, Tiffany Chang, et al.
Blood|April 25, 2012
Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpuraLuca A Lotta, Haifeng M Wu, Ian J Mackie, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 17, 2021
Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus updateDaniel P Hart, Jayanthi Alamelu, Neha Bhatnagar, et al.
British Journal of Clinical Pharmacology|April 22, 2021
Validation of a perioperative population factor VIII pharmacokinetic model with a large cohort of pediatric hemophilia a patientsTim Preijers, Ri Liesner, Hendrika C A M Hazendonk, et al.
Blood|April 5, 2013
Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN studySamantha C Gouw, H Marijke van den Berg, Kathelijn Fischer, et al.
British Journal of Haematology|July 13, 2017
Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - the impact of prophylactic treatmentNadine G Andersson, Günter Auerswald, Chris Barnes, et al.
Blood|February 17, 2019
Characterization and treatment of congenital thrombotic thrombocytopenic purpuraFerras Alwan, Chiara Vendramin, Ri Liesner, et al.
Genome Medicine|May 8, 2015
Human phenotype ontology annotation and cluster analysis to unravel genetic defects in 707 cases with unexplained bleeding and platelet disordersSarah K Westbury, Ernest Turro, Daniel Greene, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
British Journal of Haematology|March 24, 2020
Product type and the risk of inhibitor development in nonsevere haemophilia A patients: a case-control studyAlice S van Velzen, Corien L Eckhardt, Marjolein Peters, et al.
Haematologica|January 11, 2020
Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet studyChristoph Male, Nadine G Andersson, Anne Rafowicz, et al.
Blood|November 8, 2019
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitorsGuy Young, Ri Liesner, Tiffany Chang, et al.
Blood|April 25, 2012
Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpuraLuca A Lotta, Haifeng M Wu, Ian J Mackie, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|August 17, 2021
Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus updateDaniel P Hart, Jayanthi Alamelu, Neha Bhatnagar, et al.
British Journal of Clinical Pharmacology|April 22, 2021
Validation of a perioperative population factor VIII pharmacokinetic model with a large cohort of pediatric hemophilia a patientsTim Preijers, Ri Liesner, Hendrika C A M Hazendonk, et al.
Blood|April 5, 2013
Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN studySamantha C Gouw, H Marijke van den Berg, Kathelijn Fischer, et al.
British Journal of Haematology|July 13, 2017
Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - the impact of prophylactic treatmentNadine G Andersson, Günter Auerswald, Chris Barnes, et al.
Blood|February 17, 2019
Characterization and treatment of congenital thrombotic thrombocytopenic purpuraFerras Alwan, Chiara Vendramin, Ri Liesner, et al.
Genome Medicine|May 8, 2015
Human phenotype ontology annotation and cluster analysis to unravel genetic defects in 707 cases with unexplained bleeding and platelet disordersSarah K Westbury, Ernest Turro, Daniel Greene, et al.
Pageof 6